Preeclampsia, Intra-uterine Growth Restriction
Conditions
Keywords
3D Power Doppler, uteroplacental vascularization, preeclampsia, intra-uterine growth restriction, placental morphology
Brief summary
Introduction Preeclampsia (PE) and intra-uterine growth restriction (IUGR) are two major pregnancy complications related to chronic utero-placental hypoperfusion. Three-dimensional power Doppler (3DPD) angiography has been used for the evaluation of utero-placental vascularisation and three vascular indices have been calculated: the vascularisation index (VI), flow index (FI) and vascularisation-FI (VFI). However, several technical endpoints hinder the clinical use of 3DPD as physical characteristics and machine settings may affect 3DPD indices, and so its clinical significance is not yet clear. Objectives The primary objective is to better understand the clinical significance of 3DPD indices by evaluating the relationship between these indices and placental morphometry. Secondary objectives are (i) to determine the impact of machine settings and physical characteristics on 3DPD indices, and (ii) to evaluate physio-pathological placental vascularisation patterns. Methods and analysis This is a prospective controlled study. We expect to include 112 women: 84 with normal pregnancies and 28 with PE and/or IUGR (based on our former cohort study on 3DPD indices for PE and/or IUGR prediction (unpublished data)). Within 72 h before planned or semi-urgent caesarean section, utero-placental 3DPD images with five different machine settings will be acquired. Placentas will be collected and examined after surgery and stereological indices (volume density, surface density, length density) calculated. The 3DPD indices (VI, FI and VFI) of the placenta and adjacent myometrium will be calculated. Correlation between Doppler and morphological indices will be evaluated by Pearson or Spearman tests. Agreement between 3DPD indices and morphological indices will be assessed by Bland and Altman plots. The impact of Doppler settings and maternal characteristics on 3DPD indices will be evaluated with a multivariate linear regression model.
Interventions
DEVICEDoppler
acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
Sponsors
Central Hospital, Nancy, France
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
General Inclusion Criteria: * Age ≥18 years and ≤65 years Fetal anomalies * Gestational age ≥30 gestational weeks * With social insurance * With written consent for participation * With medical examination Physiological group Inclusion Criteria * Hospitalised pregnant women with scheduled or semi-urgent caesarean section according to national HAS recommendations or Hospitalised pregnant women with scheduled vaginal delivery. * Normal pregnancy issues * Normal fetal morphology Pathological group Inclusion Criteria * Pregnant women with preeclampsia and/or IUGR pregnancy * Hospitalised pregnant women with scheduled or semi-urgent caesarean section or hospitalised pregnant women with scheduled vaginal delivery.
Exclusion criteria
* Fetal morphological abnormalities that may influence fetal circulation * Maternal or fetal vital urgency * Multiple pregnancy * Non-placental origin IUGR * Language barrier * Patient under legal protection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure of 3D power Doppler indice : the vascularization index (VI) | through study completion, an average of 42 month |
| Measure of 3D power Doppler indice : blood flow (the flow index (FI) | through study completion, an average of 42 month |
| Measure of of 3D power Doppler indice : the vascularization-flow index (VFI) | through study completion, an average of 42 month |
| Measure of volume density (morphological analysis) | through study completion, an average of 42 month |
| Measure of surface density (morphological analysis) | through study completion, an average of 42 month |
Countries
France
Contacts
Primary ContactOlivier MOREL, MD, PhD
Backup ContactAboubaker CHIRIFI
Outcome results
None listed